Egypt achieves self-sufficiency in blood products thanks to Grifols

 

Griffols has achieved clinical self-sufficiency in blood products in Egypt through its strategic alliance Grifols Egypt for Plasma Derivatives (GEPD)This health and economic milestone allows the North African country to stop depending on external imports to supply itself with essential medicines, ensuring national health sovereignty and boosting a multi-million dollar investment in local infrastructure.

 

Health sovereignty: the end of external dependence

 

Through this project, Egypt Egypt has become the sixth country in the world to achieve self-sufficiency in plasma, a critical resource for treating chronic, rare, and bleeding disorders. Until now, the Egyptian healthcare system relied almost entirely on imports, primarily from [unspecified countries]. United States, which represented a structural vulnerability for a population of more than 115 million inhabitants.

 

The public-private partnership signed in 2020 has enabled the deployment of a comprehensive ecosystem. Currently, GEPD It guarantees the regular distribution of immunoglobulins, albumin, and clotting factors to public hospitals and health centers. According to the company, more than one million vials of medication produced with Egyptian plasma have already been delivered, and more than 100.000 free medical checkups have been performed on donors.

 

Economic impact and key figures of the project

 

Beyond the medical milestone, the operation of Griffols It represents a substantial engine of economic development for the region. The company estimates that its contribution to Egypt's Gross Domestic Product (GDP) will grow exponentially over the next decade thanks to the direct, indirect, and induced activity of the fractionation plant, the network of centers, and the associated logistics.

 

 

Economic Indicator	Figures and Forecasts
Contribution to GDP (2025)	55 millones de euros
Contribution to GDP (Estimate 2030)	More than 272 million euros annually
Direct Investment (Plan 2026-2029)	209 million euros (approx.)
Total Economic Impact (2026-2029)	Over 700 million euros
Current Employment (Direct/Total)	1.200 direct / >15.000 total (including indirect and induced)
Annual Employment Forecast (Future)	186.000 new jobs (44.700 direct)

 

Industrial infrastructure and technical training

 

To sustain this model of self-sufficiency, Griffols It has developed a complex infrastructure that covers the entire value chain, replicating the quality standards that the company has applied since 1971. The physical and training deployment includes:

 

Donation Network: Currently, 16 donation centers are operating, with plans to add four more during 2026. All have passed the controls of the PPTA and European authorities.

 

Local Production: The construction of a plasma processing plant is nearing completion, the first phase of which will be operational in 2026, complemented by an analysis laboratory and an integrated logistics center.

 

Training (Grifols Academy): The first African institution dedicated to plasmapheresis has been inaugurated in Cairo. Grifols Academy for Plasmapheresis, which has already provided more than 170.000 hours of training to ensure that local staff can operate the system autonomously.

 

Egypt as a Regional Hub for the Middle East and Africa

 

The company's strategy, reinforced by the recent appointment of Tomás Dagá as vice-chairman of the board of GEPDIt transcends Egyptian borders. Once internal needs are met, the plasma surplus will open up trade opportunities with neighboring countries.

 

Egypt's geopolitical position allows it to emerge as a hub regional export of plasma-derived medicines for Africa, Middle East and potentially EuropeAccording to Dagá, this self-sufficiency model is an "example for other countries seeking to guarantee safe and sustainable access to essential plasma therapies," reducing dependence on volatile external markets.

 

Key points and frequently asked questions about self-sufficiency in Egypt

What medicines are now produced locally in Egypt?
Thanks to the alliance with Grifols, Egypt produces immunoglobulins, albumin and clotting factors using plasma from local donors, covering treatments for chronic diseases and bleeding disorders without depending on imports.

What is the employment impact of the GEPD project?
Currently, the project has created 1.200 direct, highly skilled technical jobs and more than 14.000 indirect and induced jobs. It is estimated that the growth plan will generate more than 180.000 new jobs annually in the future.

When will the new production plant be operational?
The first phase of the plasma processing plant in Egypt will be operational in 2026. Currently, the country already has 16 active donation centers and a comprehensive analysis and logistics laboratory.